Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.36 |
| ▸ | CDK7 | P50613 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2659263 | 0.76 | L3MBTL1 (0.37) | ABL1DYRK1AKEAP1PIK3C3TGFBR1 | |
| SCHEMBL20936361 | 0.74 | KEAP1 (0.36) | DYRK1AKEAP1PIK3C3NUDT1MEN1 | |
| SCHEMBL10830647 | 0.74 | PIK3C3 (0.35) | DYRK1AKEAP1PIK3C3MAOBNUDT1 | |
| SCHEMBL2396040 | 0.74 | DYRK1A (0.43) | ABL1DYRK1AKEAP1PIK3C3NUDT1 | |
| SCHEMBL3194422 | 0.74 | PIK3C3 (0.51) | ABL1DYRK1APIK3C3TGFBR1 | |
| SCHEMBL17804189 | 0.70 | ABL1 (0.40) | ABL1PDGFRACSNK1A1CDK7BTK | |
| SCHEMBL22490652 | 0.70 | MAOB (0.43) | DYRK1AKEAP1TGFBR1MAOBMEN1 | |
| SCHEMBL10830676 | 0.70 | ABL1 (0.36) | ABL1PDGFRACSNK1A1CDK7BTK | |
| SCHEMBL23697854 | 0.69 | PIK3C3 (0.35) | DYRK1AKEAP1PIK3C3 | |
| SCHEMBL20852791 | 0.69 | SSTR4 (0.32) | DYRK1AKEAP1PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522595-B2 | Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-12365685-B2 | Substituted fused aromatic ring derivative, composition and use thereof | SHENZHEN TARGETRX, INC. (CN) | 2025-07-22 | — | — | US | disclosed |
| WO-2025051148-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 北京鞍石生物科技股份有限公司 | 2025-03-13 | — | — | WO | disclosed |
| CN-119320383-A | Nitrogen-containing heteroaryl compound, and preparation method and application thereof | 北京鞍石生物科技股份有限公司 | 2025-01-17 | — | — | CN | disclosed |
| EP-3904355-B1 | SUBSTITUTED FUSED AROMATIC RING DERIVATIVE, COMPOSITION AND USE THEREOF | SHENZHEN TARGETRX INC (CN) | 2024-11-20 | — | — | EP | disclosed |
| CN-117157284-A | CTLA-4 small molecule degradation agent and application thereof | 苏州国匡医药科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20220106305-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. | 2022-04-07 | — | — | US | disclosed |
| US-20220098204-A1 | SUBSTITUTED FUSED AROMATIC RING DERIVATIVE, COMPOSITION AND USE THEREOF | SHENZHEN TARGETRX, INC. (CN) | 2022-03-31 | — | — | US | disclosed |
| EP-3921316-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | Biogen MA Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3904355-A1 | SUBSTITUTED FUSED AROMATIC RING DERIVATIVE, COMPOSITION AND USE THEREOF | Shenzhen TargetRx, Inc. (CN) | 2021-11-03 | — | — | EP | disclosed |
| EP-2121687-A2 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2009-11-25 | — | — | EP | disclosed |
| EP-2114941-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | Astex Therapeutics Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009047522-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009047522-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009047506-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009047506-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | WO | disclosed |
| WO-2008078100-A2 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008078100-A2 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008078091-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008078091-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098204-A1 | SUBSTITUTED FUSED AROMATIC RING DERIVATIVE, COMPOSITION AND USE THEREOF | BRAF, ALK, TYRO3 | ABL1 11/4885PDGFRA 867/4885CSNK1A1 147/4885 |
| US-20220106305-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | ENGASE, UGGT1, MGAT3 | ABL1 2258/4885PDGFRA 1690/4885CSNK1A1 1868/4885 |
| US-12365685-B2 | Substituted fused aromatic ring derivative, composition and use thereof | BRAF, ALK, TYRO3 | ABL1 11/4885PDGFRA 867/4885CSNK1A1 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.